TFN Archive
Articles By Category
American Life
- Where The Buffalo Roam: Software executive Jeff Hawn in trouble for bison killings
- Clowns & Harlots: My Missionary Position
- Random House pulls Sherry Jones’ “Jewel of Medina”: Corporate cowardice or clever marketing ploy?
- Clowns and Harlots: Safe at Home
- Tim Russert: Written on water
Editor's Pic
- Insiders buying big time at Stewart Enterprises (STEI)
- Sun sets on solar? SPWRA, FSLR, DSTI, ENER in double-digit tailspin
- Adult education stocks plummet: Opportunity for STRA, DV, CECO, CPLA?
- Stem cell stocks: GERN, STEM, OSIR still riding high, but beware of politics
- Potash: No Miracle Gro for your Portfolio
Gold & Resources
- Inflation or Deflation: Wher is gold headed?
- Investing in gold: An easy call
- Gold: The latest cure for cancer
- 2009: The year of the letdown
- Potash: No Miracle Gro for your Portfolio
International Investing
- Cuba: Investor’s paradise or fool’s trap?
- A-Power Energy (APWR) up over 30% on Q4 results
- International Diversification: A 2-for-1 deal
- Brilliance China Automotive (BCAHY) ready for Europe?
- China starts to wonder if it made the right choice
Investment Strategies
- Emotional Investing: Save the tears for a funeral
- Best stock for a nuclear North Korea
- DryShips: A traders dream come true?
- Blockbuster makes a move. Should Netflix be scared?
- Goldman Sachs (GS) may be first to say “thanks, but no thanks” to TARP
News that Matters
- Tightwad Investing: McDonalds rules the value menu
- A powerful and paralyzing shot to the jaw
- Don’t trust the Dow. It’s a liar
- Playing a potential refinery strike
- A grim day on Wall Street has some upside
Oil & Energy
- MDU Resources: The best utility of them all?
- Where did all the drillers go?
- Investing in Sirius XM Satellite
- Frontier Oil: Buy low, sell high
- In-and-out strategies for alternative investment profits
Options
- Perfect time to dive into the options market
- Use options to leverage powerful gains
- Under Armour: A stock just as hyped as its products
- Strategic Options Update: “These options went up 50% since 9:45 this morning…”
- Best Options Play: Leverage FDA approval in this $2.55 stock into potential 300% options gains
